Seeking Alpha

GSK JV wins FDA approval for HIV drug

  • GlaxoSmithKline (GSK) joint venture company ViiV Healthcare has won FDA approval for its once-daily HIV pill Tivicay.
  • In a trial released last year, a combination of Tivicay and other antiretroviral drugs reduced the HIV virus to undetectable levels in more people than Gilead's (GILD) Atripla, the world's top-selling treatment in the field. Another rival drug is Merck's (MRK) Isentress, whose sales last year were $1.5B.
  • GlaxoSmithKline owns 76.5% of ViiV, Pfizer (PFE) 13.5% and Japan's Shionogi 10%.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: